Screening for Multisystem Risk During Preventive Health Visits: A Comprehensive Review

Abstract

Screening for multisystem risk during preventive health visits is critical for early identification of individuals at risk for complex, interrelated conditions spanning cardiovascular, metabolic, renal, hepatic, and neuropsychiatric systems. This review synthesizes current evidence and guideline-based approaches to multisystem risk assessment, integrating epidemiological data, underlying pathophysiological mechanisms, major risk factors, clinical features, and diagnostic strategies. It discusses established and emerging management paradigms, highlights recent advances in biomarker and digital health technologies, and provides practical recommendations for clinicians. The article aims to enhance the understanding and application of multisystem risk screening in routine practice, facilitating timely interventions and improved patient outcomes.

Introduction

Preventive health visits provide a valuable opportunity to identify and mitigate multisystem risk factors before the onset of overt disease. Unlike single-system assessments, multisystem screening acknowledges the interconnectedness of modern morbidity, wherein cardiovascular, metabolic, hepatic, renal, and neuropsychiatric disorders frequently co-occur and share pathogenic pathways. Early detection through comprehensive screening can profoundly impact patient trajectories by enabling timely, targeted interventions. This review critically appraises the rationale, methods, and implications of multisystem risk screening, with a focus on evidence-based practices relevant to primary and specialty care providers.

Epidemiology / Disease Burden

Multisystem risk is increasingly prevalent due to rising rates of obesity, sedentary lifestyles, aging populations, and environmental stressors. The global burden of diseases such as diabetes, hypertension, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NAFLD), and depression has led to a pronounced rise in multimorbidity. Epidemiological data from large cohorts, including NHANES and the UK Biobank, reveal that up to 30% of adults over 50 harbor risk factors for at least two major chronic conditions. Importantly, the presence of multisystem risk factors is associated with increased mortality, accelerated functional decline, and higher healthcare utilization, underscoring the imperative for early, integrated risk assessment.

Pathophysiology

Multisystem risk arises from overlapping pathophysiological mechanisms, notably chronic inflammation, oxidative stress, insulin resistance, dyslipidemia, endothelial dysfunction, and neurohormonal activation. These processes create a milieu conducive to the development of atherosclerosis, hepatic steatosis, renal microvascular injury, and neurodegeneration. For example, metabolic syndrome exemplifies the convergence of these pathways, linking abdominal obesity, hypertension, hyperglycemia, and dyslipidemia to increased cardiovascular and renal risk. Genetic predispositions, epigenetic modifications, and environmental exposures further modulate individual susceptibility, highlighting the need for personalized screening strategies.

Risk Factors

Established risk factors for multisystem disease include age, male sex, family history of chronic disease, tobacco use, poor diet, physical inactivity, psychosocial stress, and socioeconomic deprivation. Specific conditions such as type 2 diabetes, hypertension, and obesity serve as sentinel markers for broader multisystem risk. Novel risk factors, including sleep disorders, chronic infections, and air pollution, are increasingly recognized. Certain populations, such as ethnic minorities and individuals with mental health disorders, are disproportionately affected, calling for tailored screening protocols in these groups.

Clinical Features

Clinical manifestations of multisystem risk often remain subclinical in early stages. However, subtle findings—such as elevated blood pressure, microalbuminuria, abnormal liver enzymes, increased waist circumference, and depressive symptoms—may signal underlying pathology. As disease progresses, overlapping symptoms may develop, including fatigue, cognitive impairment, exertional dyspnea, and peripheral edema. The presence of multiple risk factors should prompt a high index of suspicion for impending multisystem involvement and consideration of comprehensive evaluation.

Diagnosis

Diagnosis of multisystem risk relies on a combination of history, physical examination, laboratory tests, and validated risk assessment tools. Key investigations include fasting glucose, HbA1c, lipid profile, renal function tests (eGFR, urine albumin-to-creatinine ratio), liver function tests, blood pressure measurement, anthropometry, and mental health screening instruments (e.g., PHQ-9). Composite scoring systems, such as the ASCVD risk estimator, Framingham risk score, and QRISK, offer quantifiable risk stratification. Emerging modalities—such as advanced imaging (carotid intima-media thickness, coronary calcium scoring) and multi-omics biomarkers—hold promise for refining risk prediction but require further validation.

Treatment & Management

Management of multisystem risk is anchored in lifestyle modification, pharmacotherapy, and integrated care models. Evidence strongly supports interventions such as dietary optimization (e.g., DASH or Mediterranean diets), structured physical activity, weight reduction, and smoking cessation. Pharmacological agents—statins, antihypertensives, SGLT2 inhibitors, GLP-1 receptor agonists, and antidepressants—may be indicated based on individual risk profiles. Multidisciplinary collaboration, patient education, and digital health tools (e.g., remote monitoring, telemedicine) enhance adherence and outcomes. Regular follow-up and dynamic risk reassessment are essential components of ongoing management.

Recent Advances / Emerging Therapies

Recent advances include the development of polygenic risk scores, novel biomarkers (e.g., high-sensitivity troponin, NT-proBNP, fibroblast growth factors), and expanded use of wearable technology for continuous monitoring of physiological parameters. Artificial intelligence algorithms are being integrated with electronic health records to facilitate automated risk stratification and personalized screening schedules. Emerging therapies, such as dual SGLT1/2 inhibitors and anti-inflammatory biologics, are under investigation for their multisystem benefits, particularly in high-risk populations. Additionally, point-of-care diagnostic platforms and digital decision-support tools are streamlining risk identification in diverse healthcare settings.

Guideline Recommendations

Major guidelines from organizations such as the American Heart Association (AHA), American Diabetes Association (ADA), and Kidney Disease: Improving Global Outcomes (KDIGO) advocate for periodic, multisystem risk screening in adults, particularly those over 40 or with established risk factors. Recommended intervals and modalities vary, but consensus emphasizes integration of cardiovascular, metabolic, renal, hepatic, and mental health assessments into routine preventive visits. Risk calculators should be employed to inform individualized care plans, and shared decision-making is encouraged when initiating pharmacotherapy or intensive lifestyle interventions. Screening should be culturally competent and sensitive to disparities in access and outcomes.

Conclusion

Comprehensive screening for multisystem risk during preventive health visits is an evidence-based strategy that can significantly reduce the burden of chronic disease and improve long-term patient outcomes. By synthesizing epidemiological trends, mechanistic insights, and guideline-driven recommendations, clinicians can implement effective, personalized screening protocols. Ongoing research and technological innovation promise to further refine risk assessment and intervention strategies, supporting the ultimate goal of proactive, patient-centered care in the prevention of multisystem disease.